Disclosure under Regulation 30 of SEBI Listing Regulations
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong FY2026 results with consolidated revenue from operations growing 37% to Rs. 2,02,298.54 lakhs from Rs. 1,47,683.73 lakhs in FY2025. Profit after tax increased 40% to Rs. 36,399.84 lakhs from Rs. 26,010.81 lakhs. The Board recommended a final dividend of Rs. 34 per share (340% on face value of Rs. 10). Statutory auditors MSKA & Associates LLP issued unmodified opinions on both standalone and consolidated financial results. The company also announced capacity expansion at its Unit 1 in Telangana - adding 120.5KL capacity at an investment of Rs. 143.4 crores over 12-18 months to meet growing customer demand. Additionally, Dr. Mauricio Futran was appointed as Additional Director.
Strong financial performance with 37% revenue growth and 40% PAT growth signals healthy business momentum. The capacity expansion indicates management confidence in sustained demand. Clean audit opinion removes key risk concerns for investors.